The Dukes staging system: a cornerstone in the clinical management of colorectal cancer

Haq, Asif; Schneeweiss, J; Kalsi, Vinay; Arya, Manit

doi:10.1016/s1470-2045(09)70157-3

Cited by 26 publications

(25 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Figure 2C compares the methanethiol content (2472.8 eV peak height) in the samples for all the spectra plotted in figure 2B. For the patients with colon cancer the state of progress was classified from A to D in accordance with the Dukes' staging system 27. We applied a homogeneity of variance t test to the raw data obtained for the colon cancer and healthy groups and obtained F =837.3, first degree of freedom=19.0, second degree of freedom=14.0 and p=2.2×10 −6 .…”

Section: Resultsmentioning

confidence: 99%

Generation of gaseous sulfur-containing compounds in tumour tissue and suppression of gas diffusion as an antitumour treatment

Yamagishi¹,

Onuma²,

Chiba³

et al. 2011

Gut

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Generation of gaseous sulfur-containing compounds in tumour tissue and suppression of gas diffusion as an antitumour treatment

Yamagishi¹,

Onuma²,

Chiba³

et al. 2011

Gut

View full text Add to dashboard Cite

show abstract

“…Colorectal cancer stage was extracted from pathology records held by the QCR (Krnjacki et al, 2008) and then classified based on the Dukes staging system (Haq et al, 2009). To increase accuracy (Krnjacki et al, 2008) and reduce problems with sparse data, stage was grouped into three categories: early (localized/ non-localized), advanced (regional/distant) and unknown.…”

Section: Stage At Diagnosismentioning

confidence: 99%

Spatial inequalities in colorectal and breast cancer survival: Premature deaths and associated factors

et al. 2012

View full text Add to dashboard Cite

This study examines the influence of cancer stage, distance to treatment facilities and area disadvantage on breast and colorectal cancer spatial survival inequalities. We also estimate the number of premature deaths after adjusting for cancer stage to quantify the impact of spatial survival inequalities. Population-based descriptive study of residents aged <90 years in Queensland, Australia diagnosed with primary invasive breast (25,202 females) or colorectal (14,690 males, 11,700 females) cancers during 1996-2007. Bayesian hierarchical models explored relative survival inequalities across 478 regions. Cancer stage and disadvantage explained the spatial inequalities in breast cancer survival, however spatial inequalities in colorectal cancer survival persisted after adjustment. Of the 6,019 colorectal cancer deaths within 5 years of diagnosis, 470 (8%) were associated with spatial inequalities in non-diagnostic factors, i.e. factors beyond cancer stage at diagnosis. For breast cancers, of 2,412 deaths, 170 (7%) were related to spatial inequalities in non-diagnostic factors. Quantifying premature deaths can increase incentive for action to reduce these spatial inequalities.

show abstract

“…Locoregional recurrence of the tumor after curative resection still remains problematic. Up to now, the only reliable predictor of prognosis for patients with colorectal cancer is tumor staging by the Dukes system[2]. It is therefore important to identify other potential clinico-histopathological markers that can predict the aggressive behavior of the tumor and also the overall survival of patients with this type of cancer.…”

Section: Introdutionmentioning

confidence: 99%

The potential of carcinoembryonic antigen, p53, Ki-67 and glutathion Stransferase-π as clinico-histopathological markers for colorectal cancer

Shi

Wen

et al. 2010

Journal of Biomedical Research

View full text Add to dashboard Cite

ObjectiveColorectal cancer is one of the major contributors to cancer death worldwide. Lack of reliable colorectal cancer markers has hampered the management of these cancer patients. Our main purpose was to study the correlation between histopathological variables of colorectal adenocarcinomas and identify histopathological markers that are of prognostic value in patients with colorectal cancer.MethodsIn the present study, we examined the expression of carcinoembryonic antigen (CEA), p53, Ki-67 and glutathion Stransferase (GST) -π by using immunohistochemical staining methods in 126 colorectal carcinoma patients and evaluated the lymph node metastasis status in these patients by histopathological examination.ResultsThe positive rates of CEA, p53, Ki-67 and GST-π expression in the colorectal cancer tissue specimens examined were 95.23%, 55.56%, 53.38% and 82.30%, respectively. Expression of p53 and Ki-67 was significantly correlated with the Dukes stages of the tumor, with higher levels of these proteins in Dukes'C and D tumors than those in Dukes' A and B tumors. Furthermore, the expression of p53, GST-π and Ki-67 correlated with prognosis of patients with colorectal cancer. Additionally, the expression of p53 in colorectal cancer was closely related to the expression of Ki-67 and the expression of GST-π was directly correlated with that of p53.ConclusionThe expression of CEA, p53, Ki-67 and GST-π was correlated with various clinical features of patients with colorectal cancer. The combined use of these histopathological markers appeared to be a promising tool in predicting the prognosis of patients with this type of cancer.

show abstract

The Dukes staging system: a cornerstone in the clinical management of colorectal cancer

Cited by 26 publications

References 2 publications

Generation of gaseous sulfur-containing compounds in tumour tissue and suppression of gas diffusion as an antitumour treatment

Generation of gaseous sulfur-containing compounds in tumour tissue and suppression of gas diffusion as an antitumour treatment

Spatial inequalities in colorectal and breast cancer survival: Premature deaths and associated factors

The potential of carcinoembryonic antigen, p53, Ki-67 and glutathion Stransferase-π as clinico-histopathological markers for colorectal cancer

Contact Info

Product

Resources

About